Articles By Jack Cush, MD
Preventing Hepatitis B Reactivation Due to Immunosuppressive Drug Treatments
Reactivation of hepatitis B virus infection can have devastating consequences, especially amongst those patients receiving immunosuppressive therapy.
Read ArticleKnee Replacement and the Physical Terrorist
Experience is a great teacher. My experience with knee replacement surgery has taught me the integral importance of the physical therapist in individual outcomes.
Read Article
New CPT Chronic Disease Management Code 99490
The new Medicare Physician Fee Schedule will allow for reimbursement for chronic care management services (CCM).
Read ArticleTen Pregnancy Takeaways from the ACR Reproductive Health Summit
In January 2014 the ACR convened a "Reproductive Health Summit" in Washington, DC to examine our understanding and knowledge of Pregnancy and Lactation issues in women with Rheumatic diseases. Key Stakeholders from the FDA, NIH, Womens advocacy groups, Dermatology, Gastrenterology, ACR and Pharma were asked to discuss what is know and what our unmet needs are.
Read Article
Chikungunya rises in the US and Worldwide
The chikungunya epidemic has grown significantly in the Western hemisphere with an additional 3,000 cases worldwide during the past week.
Read Article
Psoriatic Arthritis Has a New FDA Approved DMARD - Apremilast
In March 2014 the FDA approved apremilast (Otezla) for use in psoriatic arthritis based on three large"Palace" trials involving 1493 psoriatic arthritis patients. This ACR Hotline reviews the drugs use, efficacy, and toxicity.
Read Article
Hemophagocytic Syndrome in Adults
Hemophagocytic lymphohistiocytosis(HLH) is a rare complication of many disorders. In children, systemic JIA is by far the most common cause of HLH.
Read Article
Celebrex Goes Generic
The generic drug manufactuer Actavis joins Teva and Mylan with their lauch of celecoxib (Celebrex)in 50 mg, 100 mg, 200 mg and 400 mg capsules. In 2013 celecoxib was the 21st leading prescribed drug in the U.S. with $2.4 billion in sales as of mid 2014.
Read Article
